Indivior PLC Appoints New Chief Medical Officer

Ticker: INDV · Form: 8-K · Filed: Jun 24, 2025 · CIK: 1625297

Indivior PLC 8-K Filing Summary
FieldDetail
CompanyIndivior PLC (INDV)
Form Type8-K
Filed DateJun 24, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: executive-change, personnel

TL;DR

Indivior's CMO is out, new CMO in. Big pharma shuffle.

AI Summary

Indivior PLC announced on June 20, 2025, the departure of its Chief Medical Officer, Dr. Robert L. Johnson, effective June 20, 2025. The company also announced the appointment of Dr. Ryan K. George as the new Chief Medical Officer, effective immediately. Dr. George previously served as Senior Vice President, Global Medical Affairs.

Why It Matters

This leadership change in a key medical role could impact the company's drug development and regulatory strategies.

Risk Assessment

Risk Level: medium — Changes in key executive positions, especially in medical affairs, can introduce uncertainty regarding future strategic direction and execution.

Key Players & Entities

FAQ

What is the effective date of Dr. Robert L. Johnson's departure?

Dr. Robert L. Johnson's departure was effective June 20, 2025.

Who has been appointed as the new Chief Medical Officer?

Dr. Ryan K. George has been appointed as the new Chief Medical Officer.

When is Dr. Ryan K. George's appointment effective?

Dr. Ryan K. George's appointment is effective immediately.

What was Dr. Ryan K. George's previous role at Indivior PLC?

Dr. Ryan K. George previously served as Senior Vice President, Global Medical Affairs.

What is Indivior PLC's principal executive office address?

Indivior PLC's principal executive offices are located at 10710 Midlothian Turnpike Suite 125 North Chesterfield, VA 23235.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 24, 2025 by Dr. Robert L. Johnson regarding INDIVIOR PLC (INDV).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing